Baricitinib vs Nivolumab

Baricitinib vs Nivolumab: Overview

This comparison examines the pharmacological differences between Baricitinib and Nivolumab.

Mechanism of Action

Baricitinib: Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Baricitinib — 12 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Baricitinib — C16H17N7O2S.

Molecular Weight: Baricitinib — 371.4170 g/mol.

Type: Baricitinib — Small molecule; Nivolumab — Antibody.